Drug Profile
Research programme: Pim kinase inhibitors - Ryvu Therapeutics
Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Selvita
- Developer Ryvu Therapeutics
- Class Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Proto oncogene proteins c pim 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Lymphoma
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)
- 02 Oct 2019 Selvita is now called Ryvu Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Poland (PO)